ライフサイエンスコーパス: haemagglutination

1 mutations of psaE and psaF caused defective haemagglutination.

2 inia pseudotuberculosis pH6 antigen mediates haemagglutination and adhesion to cultured mammalian cel

3 and that mutations of these residues abolish haemagglutination and binding to type IV collagen.

4 In Jos, ovotransferrin concentration, haemagglutination and haemolysis titres increased 12 wee

5 (x) ) and ovotransferrin concentrations, and haemagglutination and haemolysis titres) over two annual

6 oxide and ovotransferrin concentrations, and haemagglutination and haemolysis titres), body mass and

7 n of these surface structures, which mediate haemagglutination and have a demonstrated role in virule

8 3, exhibited functional attributes including haemagglutination and neuraminidase inhibition.

9 binding by B. burgdorferi is associated with haemagglutination and we have identified a 26 kDa protei

10 ard laboratory tests (the Treponema pallidum haemagglutination assay [TPHA] and the RPR test).

11 The lectin content was analyzed using a haemagglutination assay and a Competitive Indirect Enzym

12 significant inhibition of P fimbria-mediated haemagglutination assay of uropathogenic Escherichia col

13 Haemagglutination assay proved it non-lectin.

14 cteria-killing ability (BKA), haemolysis and haemagglutination assays.

15 antibodies that inhibited mannose-resistant haemagglutination by ETEC expressing CFA/I, CS4 and CS14

16 E. coli chi7122 conferred mannose-resistant haemagglutination (HA) and curli production to E. coli H

17 ed that the psaABC genes were sufficient for haemagglutination if they were expressed by a heterologo

18 s formed high levels of A/Cal-specific serum haemagglutination-inhibiting antibodies and were solidly

19 HD-MAP administration of 2.5 mug HA induced haemagglutination inhibition (HAI) and microneutralisati

20 We tested samples with a haemagglutination inhibition (HAI) assay to measure anti

21 Here we analysed 200,000 haemagglutination inhibition (HAI) titrations from ferre

22 Haemagglutination inhibition (HI) assay for IIV strains

23 ndividuals in Guangzhou, China, using 67,683 haemagglutination inhibition (HI) assay measurements aga

24 Samples with a haemagglutination inhibition (HI) titre >/=1ratio40 were

25 nza infection or vaccination and fit them to haemagglutination inhibition (HI) titres from 5 groups o

26 In the baseline serum samples from 2008, haemagglutination inhibition and microneutralisation ant

27 Antibody titres were measured by use of haemagglutination inhibition and microneutralisation ass

28 tal transfer of antibodies by measurement of haemagglutination inhibition and microneutralization tit

29 traditional antigenic characterization using haemagglutination inhibition and promote selection of HA

30 ersion and seroprotection, all determined by haemagglutination inhibition antibody assay.

31 fficacy of high-titre anti-influenza plasma (haemagglutination inhibition antibody titre >=1:80) comp

32 t-boosted regression model trained on annual haemagglutination inhibition antibody titre inputs, we i

33 this influenza nanoparticle vaccine elicited haemagglutination inhibition antibody titres more than t

34 y and efficacy of anti-influenza plasma with haemagglutination inhibition antibody titres of 1:80 or

35 tion assay (titre >=20) and 97% (90-100%) by haemagglutination inhibition assay (titre >=40).

36 Seroconverison was confirmed by haemagglutination inhibition assay for influenza A virus

37 Sera were tested in haemagglutination inhibition assay.

38 and compared the proportion of samples with haemagglutination inhibition titre 1:32 or more (deemed

39 The proportion of samples with haemagglutination inhibition titre 1:32 or more ranged f

40 difference in the proportion of samples with haemagglutination inhibition titre equal to or above 1:3

41 Participants had to have an initial haemagglutination inhibition titre of at most 1/20, be a

42 gG in oral fluid was closely correlated with haemagglutination inhibition titre.

43 he placebo group had a four-fold increase in haemagglutination inhibition titres (group geometric mea

44 ted participants had a four-fold increase in haemagglutination inhibition titres (group geometric mea

45 hIVIG treatment produced a robust rise in haemagglutination inhibition titres against influenza A

46 The choice of day 7 was based on haemagglutination inhibition titres from a pilot study.

47 d high levels of influenza-specific IgG1 and haemagglutination inhibition titres to H1 virus.

48 Immunogenicity was assessed by haemagglutination inhibition titres, the percentage of p

49 Antibody responses were measured by haemagglutination inhibition, microneutralisation, and s

50 r, and one person of eleven seroconverted by haemagglutination inhibition, microneutralisation, H5N3

51 ccine gave the highest seroconversion rates: haemagglutination inhibition, six of ten; microneutralis

52 unogenicity endpoints were seroconversion by haemagglutination-inhibition (HAI), defined as a four-ti

53 come was the proportion of participants with haemagglutination-inhibition (HI) geometric mean titre (

54 subsequent immunisation were evaluated using haemagglutination-inhibition and microneutralisation ass

55 We measured antibody responses by haemagglutination-inhibition and microneutralisation.

56 Peak geometric mean titre (GMT) for haemagglutination-inhibition antibodies in the previousl

57 ed influenza vaccine induces moderate-to-low haemagglutination-inhibition antibody responses in peopl

58 Haemagglutination-inhibition antibody responses were mea

59 Importantly, higher cross-reactive haemagglutination-inhibition antibody titres against H5N

60 vaccinated with LAIV H5N2 had an increase in haemagglutination-inhibition titre of greater than four-

61 ants in the vaccine group had an increase in haemagglutination-inhibition titre of more than four-fol

62 Here we analysed haemagglutination-inhibition titres in 1,451 cross-secti

63 pe 4 pilus responsible for mannose-sensitive haemagglutination is abolished.

64 uspension of A-cells or B-cells was used for haemagglutination on the reverse grouping side.

65 by the organism which are biofilm formation, haemagglutination properties and capsule production.

66 strains exhibited a strong mannose-sensitive haemagglutination reaction with guinea pig erythrocytes,

67 Here we describe a quantitative Haemagglutination test (HAT) for the detection of antibo

68 ctive combined serology (positive T pallidum haemagglutination test and rapid plasmin reagin titre of

69 Haemagglutination test for antibodies to the receptor bi